The SLC8A3 antibody targets the solute carrier family 8 member 3 (SLC8A3), also known as the sodium-calcium exchanger 3 (NCX3), a transmembrane protein critical for maintaining cellular calcium homeostasis. NCX3 facilitates the bidirectional exchange of Na⁺ and Ca²⁺ across the plasma membrane, depending on ion gradients and membrane potential. It plays a vital role in regulating intracellular calcium levels, particularly in excitable tissues such as neurons, skeletal muscle, and cardiac cells. Dysregulation of NCX3 has been implicated in neurodegenerative diseases, muscle disorders, and cardiovascular conditions.
SLC8A3 antibodies are essential tools for studying the expression, localization, and function of NCX3 in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect NCX3 in tissue samples or cultured cells. Research utilizing SLC8A3 antibodies has shed light on its neuroprotective roles under ischemic stress, involvement in calcium signaling during muscle contraction, and potential contributions to diseases like Alzheimer's and Parkinson's.
Commercial SLC8A3 antibodies are typically raised in hosts such as rabbits or mice, with specificity validated via knockout controls or peptide blocking assays. Their applications extend to exploring therapeutic strategies targeting calcium dysregulation, making them indispensable in molecular and cellular biology research.